Subscribe to Search results

There were cost pressures related to heat-treated factor product.

Published on:

Professor Bloom stated that, "A small percentage of these freeze dried preparations contain, unavoidably, the virus of serum hepatitis and therefore potentially dangerous to the patient."

Published on:

Dr Jones "had his wrists slapped for public statements" by the CMO, Dr Donald Acheson.

Published on:

There was some evidence that some of this stock of NHS products made from unscreened donations was destroyed.

Published on:

The UK lacked the ease of access to laboratory screening to check on viral inactivation.

Published on:

There was some resistance by some clinicians to the use of heat-treated product.

Published on:

Earlier availability of virally inactivated concentrates would have made the biggest difference.

Published on:

Some Factor 8 product had been recalled, but this was probably a batch recall rather than a general recall.

Published on:

Dr Milton Mozen, the director of biochemical research and development at Cutter, emphasised in his evidence to the Institute of Medicine in the US that a heat treatment process is successful as applied by one manufacturer, it does not follow that this process would be applicable to the unique products of the other manufacturer.

Published on:

Dr Peter Fernandes stated that similar stabilisers to those which worked with the globulin could work with antihemophilic factor.

Published on:

Clive Collins stated that ,"Given the specialised medical nature of the seroconversion problem it was appropriate that my Medical Department colleagues dealt directly with the DHSS Medical staff."

Published on:

Dr Shanbrom had suggested to the executives that they should no longer take plasma from hepatitis hotspots such as downtown Los Angeles and from prisons because of the risks.

Published on:

J K Smith, Lowell Winkelman and P A Feldman reported the interim results that severe heating had been more effective in preventing transmission of non-A non-B Hepatitis than the milder heating given to at least two US commercial products.

Published on:

A clinical trial of 8Y was reported to be at a stage where several patients had safely passed the point at which first evidence of non-A non-B Hepatitis transmission would have been expected.

Published on:

Milt Mozen visited SNBTS PFC and discussed the issue of hepatitis with Jim Smith.

Published on:

Dr Peter Foster was shocked when Dr John Cash told him that the German company Behringwerke had announced at a symposium in Bonn that it was pasteurising Factor 8, as he had thought heat could not be used to inactivate virus in factor products.

Published on:

Dr John Cash established the SNBTS Coagulation Factor Study Group.

Published on:

PFC produced 11 pilot batches of "ZHT" and tested their clinical validity in late 1983.

Published on:

PFC and SNBTS prioritised dry heat treatment over pasteurisation after the the data presented at Groningen showed that it could inactivate HTLV-3.

Published on:

PFC heat treated its existing 12-month stock of Factor 8 batches manufactured as early as October 1983.

Published on: